MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Cumberland Pharmaceuticals Inc

Gesloten

4.14 -3.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.05

Max

4.27

Belangrijke statistieken

By Trading Economics

Inkomsten

-365K

-1.9M

Verkoop

1.3M

10M

EPS

-0.136

Winstmarge

-18.223

Werknemers

91

EBITDA

-1.9M

-1.8M

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-11M

62M

Vorige openingsprijs

7.18

Vorige sluitingsprijs

4.14

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Cumberland Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 apr 2025, 22:38 UTC

Populaire aandelen

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 apr 2025, 21:53 UTC

Marktinformatie

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 apr 2025, 21:44 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 apr 2025, 21:00 UTC

Top Nieuws

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 apr 2025, 20:52 UTC

Marktinformatie

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 apr 2025, 20:52 UTC

Top Nieuws

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 apr 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 apr 2025, 20:48 UTC

Top Nieuws

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 apr 2025, 20:45 UTC

Top Nieuws

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 apr 2025, 20:32 UTC

Top Nieuws

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 apr 2025, 20:21 UTC

Top Nieuws

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 apr 2025, 20:00 UTC

Top Nieuws

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 apr 2025, 19:51 UTC

Marktinformatie

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 apr 2025, 19:37 UTC

Top Nieuws

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 apr 2025, 19:32 UTC

Marktinformatie

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 apr 2025, 19:28 UTC

Top Nieuws

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 apr 2025, 19:15 UTC

Marktinformatie

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 apr 2025, 19:12 UTC

Top Nieuws

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 apr 2025, 19:11 UTC

Marktinformatie

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 apr 2025, 19:09 UTC

Marktinformatie

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 apr 2025, 19:09 UTC

Top Nieuws

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 apr 2025, 19:00 UTC

Marktinformatie

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 apr 2025, 18:53 UTC

Marktinformatie

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 apr 2025, 18:51 UTC

Marktinformatie

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 apr 2025, 18:44 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

4 apr 2025, 18:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 apr 2025, 18:44 UTC

Marktinformatie

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 apr 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 apr 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 apr 2025, 18:39 UTC

Marktinformatie

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Peer Vergelijking

Prijswijziging

Cumberland Pharmaceuticals Inc Prognose

Technische score

By Trading Central

4.27 / 4.4Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.